A thermal stability-based proteomic analysis identifies cytoplasmic PEBP1 as a mediator of mitochondrial dysfunction-induced stress response, highlighting its potential role in cellular adaptation ...

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

FFECTOR Therapeutics (NASDAQ:EFTR – Get Free Report) will likely be posting its quarterly earnings results on Tuesday, January 21st. Analysts expect eFFECTOR Therapeutics to post earnings of ($2.02) ...

Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response ...

Clinicians may one day be able to treat immune checkpoint inhibitor-related myocarditis without disrupting cancer therapy, findings from a cellular investigation showed.Individuals who die of immune ...

Iambic’s pipeline includes IAM1363, a potential best-in-class, highly selective and brain penetrant small molecule inhibitor of both wild-type and oncogenic HER2 mutants currently in a Phase 1 ...

Researchers report the ability of tofacitinib to reduce infection risk with SARS-CoV-2 in individuals who are deficient in PTPN2.

Insilico Medcine( "Insilico") , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today announced the first patient has been dosed in the global multicenter Phase I ...

thereby ensuring efficient translation of maternal mRNAs. This study identified the first known inhibitor of the CCR4-NOT complex during the OET phase in mammals, offering new insights into the ...